DalsnaFinance

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

Markets PR Newswire By PR Newswire 20 Jul 2026 07:42 1 min read
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...

DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 Broadest pivotal trial to date, enrolling patients with a wide range of DEE syndromes, the majority...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.